[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"human-immunodeficiency-virus-hiv\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:human-immunodeficiency-virus-hiv":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,41,68,88,118,147,186,212,234,261,282,314,336,366,396],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100639988","phase-1-a-clinical-trial-of-mk-8527-and-rifampin-in-adult-participants-with-latent-tuberculosis-infection-mk-8527-019-100639988",false,"NCT07600775","A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)","An Open-label, Phase 1 Study to Characterize the Effects of Rifampin on the Pharmacokinetics of MK-8527 in Adult Participants With Latent Tuberculosis Infection","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has a diagnosis of untreated latent tuberculosis infection (LTBI)\n* Has no symptoms of active tuberculosis (TB)\n* Has never received treatment for TB or LTBI\n* Other than having LTBI, is in good health\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has a diagnosis of LTBI made in the context of an outbreak\u002Fcontact-tracing investigation\n* Has a current or anticipated immunocompromised state\n* Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases\n* Has a history of cancer (malignancy)\n* Has a history of active TB\n* Has positive test results for hepatitis B surface antigen, hepatitis C antibodies, or human immunodeficiency virus","ALL","18 Years","60 Years",{"count":20,"type":21},14,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","Researchers are studying MK-8527, a new medicine for preventing HIV-1 (human immunodeficiency virus type 1) infection and want to learn if MK-8527 can be given together with rifampin. Rifampin is commonly used to treat people with latent tuberculosis infection (LTBI).\n\nThe main goal of this study is to learn what happens to MK-8527 in the body over time when given with and without the medication rifampin in participants with LTBI.",[27,28],"Human Immunodeficiency Virus (HIV)","HIV Pre-Exposure Prophylaxis","NOT_YET_RECRUITING","2026-06-30",{"date":32,"type":33},"2026-07-02","ACTUAL",{"date":35,"type":21},"2026-07-20",{"date":37,"type":21},"2027-01-19",{"name":39,"class":40},"Merck Sharp & Dohme LLC","INDUSTRY",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100598448","phase-3-a-study-of-mk-8527-to-prevent-human-immunodeficiency-virus-type-1-hiv-1-mk-8527-010-100598448","NCT07071623","A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)","A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Is confirmed Human Immunodeficiency Virus (HIV)-uninfected based on negative HIV-1\u002FHIV-2 test results\n* Has been sexually active (2 vaginal intercourse encounters with cisgender male individual(s) within the last 3 months)\n* Was assigned female sex at birth and is cisgender.\n* Weighs ≥35 kg\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has hypersensitivity or other contraindication to any component of the study interventions\n* Has evidence of acute or chronic hepatitis B infection\n* Has a history of malignancy within 5 years of screening except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer\n* Has taken cabotegravir, lenacapavir, or any other long-acting HIV prevention product at any time\n* Is receiving or is anticipated to require any prohibited therapies from 30 days prior to Day 1 through the study duration\n* Has received an HIV vaccine at any time (ie, through past participation in an investigational clinical study) or monoclonal antibodies to HIV within 12 months before Day 1",true,"FEMALE","16 Years","30 Years",{"count":53,"type":21},4580,[55],"PHASE3","Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection.\n\nThe goals of this study are to learn:\n\n* If taking MK-8527 once a month works to prevent HIV-1 infection better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day\n* About the safety of MK-8527 and if people tolerate it",[27,28],"RECRUITING","2026-06-26",{"date":61,"type":33},"2026-06-29",{"date":63,"type":33},"2025-11-10",{"date":65,"type":21},"2027-10-18",{"name":39,"class":40},30,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":48,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},"100596349","phase-3-a-clinical-study-of-mk-8527-to-prevent-human-immunodeficiency-virus-type-1-hiv-1-mk-8527-011-100596349","NCT07044297","A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)","A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Is confirmed HIV-uninfected based on negative HIV-1\u002FHIV-2 test results\n* Is a cisgender man, transgender woman (assigned male sex at birth), transgender man (assigned female sex at birth), or gender nonbinary person\n* Has had condomless receptive anal sex in the 12 months prior to screening (not including sex occurring in a mutually monogamous relationship) and has at least 1 of the following: receptive anal sex with 2 or more partners in the 3 months prior to screening (regardless of condom use), rectal or urethral gonorrhea or chlamydia or incident syphilis in the 6 months prior to screening, or any self-reported stimulant drug use with sex in the 3 months prior to screening\n* Weighs ≥35 kg\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has hypersensitivity or other contraindication to any component of the study interventions\n* Has evidence of acute or chronic hepatitis B infection\n* Has a history of malignancy within 5 years of screening except for adequately treated basal cell or squamous cell skin cancer, or in situ anal or cervical cancers\n* Has taken cabotegravir, lenacapavir, or any other long-acting HIV prevention product at any time\n* Is receiving or is anticipated to require any prohibited therapies from 30 days prior to Day 1 through the study duration\n* Has received an HIV vaccine at any time (ie, through past participation in an investigational clinical study) or monoclonal antibodies to HIV within 12 months before Day 1\n* Is expecting to donate eggs at any time during the study",{"count":76,"type":21},4390,[55],"Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection.\n\nThe goals of this study are to learn:\n\n* If taking MK-8527 once a month works to prevent HIV-1 infection as well as or better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day\n* About the safety of MK-8527 and if people tolerate it",[27,28],"2026-06-25",{"date":61,"type":33},{"date":83,"type":33},"2025-07-31",{"date":85,"type":21},"2027-07-22",{"name":39,"class":40},81,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":48,"sex":16,"minAge":96,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":117},"100599859","hiv-testing-counselor-led-care-to-catalyze-integration-of-prep-delivery-in-family-planning-clinics-100599859","NCT07089966","HIV Testing Counselor-led Care to Catalyze Integration of PrEP Delivery in Family Planning Clinics","HIV Testing Counselor-led Care to Catalyze Integration of PrEP Delivery in Family Planning Clinics: The HIV Testing Services PrEP Integration (HTS PrEP) Project","HTS PrEP","Inclusion Criteria:\n\n* ≥15 years of age\n* Accessing health services at participating public health facilities.\n* Not known to be living with HIV prior to the visit when their clinical data is first abstracted","15 Years",{"count":98,"type":21},30000,[100],"NA","This is a cluster randomized, stepped wedge implementation study to introduce HIV testing services (HTS) counselor-led PrEP care in public health clinics in Kenya.",[27,103],"HIV Pre-exposure Prophylaxis",[105,106],"PrEP","HIV Prevention","2026-06-16",{"date":109,"type":33},"2026-06-18",{"date":111,"type":33},"2025-12-01",{"date":113,"type":21},"2029-06-30",{"name":115,"class":116},"University of Washington","OTHER",1,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":48,"sex":16,"minAge":125,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":130,"conditions":131,"keywords":135,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":146},"100632938","c-3002-enhancing-cervical-cancer-screening-access-and-follow-up-care-at-cascade-clinical-sites-in-the-united-states-100632938","NCT07520188","C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States","CASCADE3002","Aim 1b Inclusion Criteria\n\n* women with Human Immunodeficiency Virus (HIV) receive care\n* ages between 25- 49\n* eligible for cervical cancer screening per national US guidelines\n\nAim 1b Exclusion Criteria • Women without an intact cervix.\n\nAim 2 Inclusion Criteria:\n\n* Clinical team members who work and provide care to women living with HIV at three clinical locations: the Center for Infectious Diseases (CID) at the University of Maryland School of Medicine in Baltimore, MD; Ponce de Leon Clinic at Emory University in Atlanta, GA; and Albany Area Primary Health Care in Albany, GA. a\n* Clinical team members will include: providers (Physicians, Nurse practitioners, Physician's Assistants, Nurses, Nursing Assistants, Medical Assistants, Pharmacists), laboratory members, or other staff involved in clinic operations.\n\nAim 2 Exclusion Criteria\n\n• Individuals who do not work for the Center for Infectious Diseases (CID) at the University of Maryland School of Medicine in Baltimore, MD or the Ponce de Leon Clinic at Emory University in Atlanta, GA","25 Years","49 Years",{"count":128,"type":21},3500,"OBSERVATIONAL","The purpose of the CASCADE-3002 project is to improve access to cervical cancer screening among women with Human Immunodeficiency Virus (HIV) receiving care at U.S.-based CASCADE clinical sites. This study will assess the cervical cancer screening cascade and identify multilevel factors that impede access to screening among women with HIV attending Infectious Disease clinics in Georgia and Maryland. In parallel, the study will explore and develop implementation strategies for human papillomavirus (HPV) self-collection to increase screening uptake, adherence, and appropriate clinical follow-up in this population at elevated risk for cervical cancer.\n\nCervical cancer remains a preventable malignancy; however, women with HIV are at substantially increased risk and experience higher rates of cervical cancer compared with women without HIV. The World Health Organization has called for the global elimination of cervical cancer as a public health problem, defined as fewer than 4 incident cases per 100,000 women annually, with targets for vaccination, screening, and treatment coverage. Although the United States has the tools to approach near-elimination, disparities in healthcare access and screening persist, particularly among women with HIV.",[27,132,133,134],"Human Papillomavirus (HPV)","Cervical Cancer","Cervical Precancer",[136],"screening","2026-06-04",{"date":139,"type":33},"2026-06-05",{"date":141,"type":21},"2026-06",{"date":143,"type":21},"2027-05",{"name":145,"class":116},"UNC Lineberger Comprehensive Cancer Center",2,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":48,"sex":16,"minAge":96,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":158,"conditions":159,"keywords":160,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":182,"leadSponsor":184,"locationsCount":146},"100637091","combacal-hiv-prevention-twics-100637091","NCT07581600","ComBaCaL HIV Prevention TwiCs","Community-based, Village Health Worker-led, eHealth-supported, Integrated HIV Prevention for People at Substantial Risk of HIV Acquisition in Rural Lesotho: Protocol for a Cluster-randomized Hybrid Type 1 effectiveness-implementation Trial Within the ComBaCaL Cohort Study","CoPrev","Inclusion Criteria:\n\n* Participant of the ComBaCaL cohort study (signed informed consent available)\n* Weight ≥ 35 kg\n* Negative HIV screening test\n* No potential exposure to HIV more than 72 hours ago (PEP eligibility window period) and less than 4 weeks ago (window period HIV test)\n* At substantial risk of HIV acquisition as per behavioural risk factors in the Lesotho's national HIV prevention and treatment guidelines:\n\n  * Report of serodiscordant partner who are not virally suppressed or have an unknown viral suppression status (either not on ART, initiated ART within the last 6 months, known virally unsuppressed or unknown virally suppression status but believed not to be taking treatment regularly)\n  * Report of sexual partner with unknown HIV status\n  * Report of unprotected sex with more than one partner in the last 6 months\n  * Report of STI by lab-testing or self-report of STI syndromic management in the last 6 months\n  * Report of exchanging money\u002Fgoods for sex in the last 6 months (as recipient and vice versa)\n  * Report of intravenous drug use with shared equipment in the last 6 months\n  * Request for biomedical HIV prevention\n\nExclusion Criteria:\n\n* Known allergies to PEP\u002Foral PrEP\n* Known glomerular filtration rate (GFR) \\\u003C 60 ml\u002Fmin or diagnosis of moderate\u002Fsevere kidney disease or kidney failure",{"count":156,"type":21},380,[100],"This cluster-randomized intervention is embedded in the ComBaCaL (Community-Based Chronic disease care Lesotho) cohort study (EKNZ ID AO\\_2022-00058, clinicaltrials.gov ID NCT05596773, Lesotho NH-REC ID 210-2022), a platform for the investigation of chronic diseases and their management in rural Lesotho that is maintained by local lay chronic care village health workers (CC-VHWs).\n\nThis study is to evaluate the effectiveness and safety of the CoPrev model in regard to biomedical HIV prevention utilization compared with an enhanced standard of care, in which VHWs assisted by a tablet-based CDS application, perform the same activities except for the prescription and\u002For delivery of PEP, oral PrEP, COC and self-injectable contraception. Additionally, this study aims to assess the outcomes and processes related to the implementation of such a model.",[27],[161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177],"Community-Based Chronic Disease Care Lesotho (ComBaCaL) cohort study","Low- and middle-income countries (LMICs)","Clinical decision support (CDS)","Community health worker (CHW)","Adolescent girls and young women (AGYW)","Pre-Exposure Prophylaxis (PrEP)","Post-Exposure Prophylaxis (PEP)","Village health worker (VHW)","Tenofovir Disoproxil Fumarate (TDF)","Lamivudine (3TC)","Dolutegravir (DTG)","Combined oral contraception (COC)","Antiretroviral therapy (ART)","Sexually transmitted infection (STI)","Levonorgestrel (LNG)","Ethinylestradiol (EE)","Trials within Cohorts (TwiCs)","2026-05-18",{"date":180,"type":33},"2026-05-22",{"date":141,"type":21},{"date":183,"type":21},"2027-06",{"name":185,"class":116},"University Hospital, Basel, Switzerland",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":22,"phases":195,"briefSummary":196,"conditions":197,"keywords":198,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":117},"100628837","the-effects-of-chiropractic-care-on-inflammation-and-quality-of-life-in-people-living-with-hiv-100628837","NCT07466836","The Effects of Chiropractic Care on Inflammation and Quality of Life in People Living With HIV","HIV","Inclusion Criteria:\n\n* Aged 18 or older\n* Medically confirmed HIV diagnosis\n* Willing to complete online surveys\n* Willing to share lab results\n* Willing to be randomized to either once weekly chiropractic care or a no treatment control condition\n\nExclusion Criteria:\n\n* Participating in another clinical\u002Fbehavioral trial related to HIV\n* Receiving chiropractic care elsewhere\n* Involved in litigation related to a physical, health-related injury\n* Has severe osteoporosis or recent spinal fracture",{"count":194,"type":21},40,[100],"The main aim of this pilot trial is to investigate the feasibility of undertaking a randomized controlled trial involving adults living with HIV. Additionally, this trial will explore potential change differences in self-reported quality of life and blood-derived immune markers between a chiropractic care group and no treatment controls.",[27],[199,200,201,202],"Human Immunodeficiency Virus","Pilot Projects","Chiropractic","Randomized Controlled Trial","2026-05-05",{"date":205,"type":33},"2026-05-08",{"date":207,"type":33},"2026-04-11",{"date":209,"type":21},"2027-03",{"name":211,"class":116},"Tyson Perez, DC, PhD",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":49,"minAge":125,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":22,"phases":221,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":117},"100638783","testing-the-feasibility-of-different-hpv-screening-and-care-strategies-for-women-living-with-hiv-100638783","NCT07576842","Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIV","CASCADE: A Feasibility Study of HPV Screening and Management Strategies Utilizing Extended Molecular HPV DNA Genotyping and HPV Viral Load in Women Living With HIV","Inclusion Criteria:\n\n* HIV-1 infection, as documented by:\n\n  1. any FDA-approved, licensed HIV rapid test performed in conjunction with screening (oral immunoblot, ELISA test kit, and confirmed by Western blot or other approved test), OR\n  2. a physician's written record that documents HIV infection with supporting information on the participant's relevant medical history and\u002For current management of HIV infection, OR\n  3. documentation of a prescription of an approved antiretroviral regimen by either possession of pill bottles or packages with prescriber's name or ARVs dispensed from an HIV clinical treatment program with participant identifiers affixed to the bottles or packages.\n* Aged 25 or older.\n* Ability to understand and the willingness to sign a written informed consent document by the participant or by the legal representative(s) of the participant.\n* Have an intact cervix.\n\nExclusion Criteria:\n\n* Current symptoms or concern for cervical cancer.\n* History of cervical, vulvar, vaginal, perianal, anal cancer or oral cancer or current symptoms of cervical, vulvar, vaginal, perianal, anal cancer or oral cancer.\n* Have undergone cervical hHSIL treatment in the past year.\n* Have a history of hysterectomy with removal of the cervix.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (including opportunistic infections of AIDS and\u002For genitourinary infections), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Any other medical condition or social situation that would put the participant, the study staff, or the study outcomes at risk, as determined by the site investigators.",{"count":220,"type":21},750,[100],"The overall goal of this study is to inform the design and establish feasibility for a future clinical trial to determine the optimal management of women living with HIV (WLWH) with high-risk human papillomavirus (hrHPV) detected on HPV-based cervical cancer screening. WLWH have a higher diversity of anogenital HPV types causing cervical high-grade squamous intraepithelial lesions (hHSIL) and invasive cancer compared to women without HIV. While there is consensus that women testing positive for HPV 16 and\u002For 18 should be immediately managed and treated, optimal management strategies for women with other hrHPV types (non-16\u002F18) are not well defined.\n\nThis prospective cohort study will enroll WLWH undergoing cervical cancer screening using primary HPV testing. Women will self-collect vaginal specimens for hrHPV testing using the Abbott Alinity m HPV assay, which provides extended HPV genotyping and a proxy for HPV viral load based on cycle threshold (CT) values. Women with hrHPV detected will return for further evaluation and treatment as indicated. A subset of women will return at Month 6 for repeat evaluation.\n\nThe study will evaluate feasibility for a future trial by examining recruitment, retention, return for evaluation, and completion of treatment. It will also explore management strategies for women with non-16\u002F18 hrHPV based on extended genotyping and HPV viral load compared to standard of care approaches using visual inspection with acetic acid (VIA).",[132,224,133,27,225],"HPV Associated Cancers","Cervical Intraepithelial Neoplasia (CIN)","2026-05-04",{"date":205,"type":33},{"date":229,"type":21},"2026-06-01",{"date":231,"type":21},"2027-06-01",{"name":233,"class":116},"University of California, San Diego",{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":22,"phases":242,"briefSummary":244,"conditions":245,"keywords":247,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":117},"100562071","phase-4-using-multiphase-optimization-strategy-most-to-optimize-a-cost-effective-sustainable-and-scalable-smoking-cessation-package-for-smokers-in-hiv-clinical-care-100562071","NCT06598397","Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care","Inclusion Criteria:\n\n* Status as HIV+\n* Age 18 or older\n* Currently smokes ≥ 5 CPD, on average, in past month\n* Positive for salivary cotinine\n* Able to understand the nature of the study and the consenting process\n* Is engaged in HIV clinical care\n* Living in larger NYC metropolitan area currently and for the next 6-8 months\n\nExclusion Criteria:\n\n* Suffers from any medical condition or contraindication precluding use of nicotine replacement therapy\n* Current use of any tobacco cessation medications (varenicline, NRT patch, nicotine gum, lozenge, spray or inhaler, or bupropion)\n* Currently participating in a smoking cessation program\n* Pregnant or nursing and plans to be in next 6 months\n* Has schizophrenia\u002Fschizo-affective disorder\n* Does not have a functioning mobile phone that can receive text messages",{"count":241,"type":21},500,[243],"PHASE4","This study's long-term goal is to improve clinical outcomes among smokers living with HIV (SLWH) by providing smoking cessation interventions in HIV clinical care that will increase the chances of quitting smoking, limits costs and burden on staff and reach many smokers living with HIV.",[27,246],"Smoking Cessation",[248,249,250,251],"MOST","multiphase optimization strategy","implementation","HIV clinical care","2026-04-08",{"date":254,"type":33},"2026-04-13",{"date":256,"type":33},"2024-10-18",{"date":258,"type":21},"2028-06-30",{"name":260,"class":116},"New York University",{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":48,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":22,"phases":270,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":117},"100513676","persuasive-health-communication-intervention-for-hivhcv-100513676","NCT05968573","Persuasive Health Communication Intervention for HIV\u002FHCV","Evaluation of a Persuasive Health Communication Intervention Designed to Increase HIV\u002FHCV Screening Among Emergency Departments Patients Who Currently, Formerly or Never Injected Drugs.","Inclusion Criteria:\n\n* ≥18 years-old\n* Speak English or Spanish, and able to provide informed consent for study participation\n* Not HIV AND HCV infected\u002FAntibody+ (per EHR review and patient report)\n* Not already participating in a HIV or HCV study (e.g., HIV PrEP, HIV vaccine)\n* Not tested for HIV OR HCV within the past 12 months (per EHR review and patient report)\n\nExclusion Criteria:\n\n* \\\u003C18 years old\n* Unable to speak Spanish or English\n* HIV or HCV positive\n* Currently enrolled in another HIV or HCV research study\n* Has tested for HIV or HCV in the past 12 months",{"count":269,"type":21},2000,[100],"A major impediment to emergency department (ED)-based HIV\u002FHCV screening success is that often ED patients at risk for, or later diagnosed with, HIV and HCV decline testing. In this R01 project, the research team will assess how well a promising, easy-to-use, one-time, minimal-training-needed, very brief persuasive health communication intervention (PHCI) increases acceptance of testing among adult ED patients who either currently, formerly or never injected drugs and initially declined HIV\u002FHCV screening. The research team will conduct a randomized, controlled trial (RCT) at EDs within the Mount Sinai Health System to compare the efficacy of the PHCI when delivered by a video vs. an HIV\u002FHCV counselor. Patients who initially declined HIV\u002FHCV screening will be stratified by injection-drug use (IDU) history cohorts: (1) current\u002Fformer PWIDs, (2) never\u002Fnon-PWIDs. Within each IDU history cohort, the research team will randomly assign participants (1:1:1) to a PHCI delivered by: (1) a video with captions, (2) a video without captions, (3) an HIV\u002FHCV counselor. This R01 project will be conducted at Mount Sinai affiliate hospitals EDs. For Aim 2, the research team will determine if screening acceptance is similar across IDU history cohorts. For Aim 3, the research team will further compare the two delivery forms of the PHCI through a health economics assessment, both independent of IDU history and within each IDU history cohort.",[27,273],"Hepatitis C (HCV)","2026-04-02",{"date":252,"type":33},{"date":277,"type":33},"2023-12-04",{"date":279,"type":21},"2026-08-01",{"name":281,"class":116},"University of South Florida",{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":22,"phases":292,"briefSummary":293,"conditions":294,"keywords":299,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":117},"100583774","the-trans-led-care-study-100583774","NCT06880705","The Trans-Led Care Study","A Gender-Affirming Stigma Intervention to Improve Substance Misuse and HIV Risk Among Transgender Women","TLC","Inclusion Criteria:\n\nEligible transgender adults must:\n\n1. be 18 years of age or older;\n2. speak primarily English;\n3. live in the U.S.;\n4. have a gender identity different from their assumed gender, or sex assigned, at birth;\n5. identify as a person of transgender experience;\n6. endorse having experienced two or more problem(s) related to alcohol or other drug use within the past 12 months.",{"count":291,"type":21},124,[100],"This study is testing a new mutual-help group called \"the TLC program\" for transgender adults who use substances or are recently in recovery. The TLC Program is based on Acceptance and Commitment Therapy or \"ACT\" which is a type of mental health counseling that focuses on using mindfulness skills to connect a person to their values and improve their mental health. The TLC Program was developed by transgender and gender diverse community members, mental health providers, and researchers.",[295,296,297,298,27],"Substance Abuse","Substance Addiction","Substance Use Disorder (SUD)","Substance Use (Drugs, Alcohol)",[300,301,302,303,304],"Substance misuse","HIV risk","Stigma","Psychological distress","Gender affirmation","2026-03-23",{"date":307,"type":33},"2026-03-27",{"date":309,"type":33},"2025-02-10",{"date":311,"type":21},"2027-07-31",{"name":313,"class":116},"Illinois Institute of Technology",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":48,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":323,"conditions":324,"keywords":325,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":117},"100625111","voluntary-hiv-screening-in-the-general-population-in-france-100625111","NCT07418385","Voluntary HIV Screening in the General Population in France","depistageVIH","Inclusion Criteria:\n\n* 18 years of age or older\n* Male or female\n* Regardless of sexual orientation\n* Whether or not they have previously undergone voluntary HIV testing\n* Agreeing to participate in the study.\n\nExclusion Criteria:\n\n* Minors\n* Refusing to participate in the study",{"count":322,"type":21},1000,"Since 2020, an increase in positive screenings for sexually transmitted infections, including HIV, has been observed.\n\nVoluntary early screening plays an important role in the national strategy for HIV care in France. There are currently several methods that allow patients to undergo voluntary screening.",[27],[191,326],"voluntary screening","2026-02-17",{"date":329,"type":33},"2026-02-18",{"date":331,"type":33},"2025-10-07",{"date":333,"type":21},"2026-09-01",{"name":335,"class":116},"Université de Reims Champagne-Ardenne",{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":344,"targetDuration":4,"studyType":22,"phases":346,"briefSummary":347,"conditions":348,"keywords":354,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":117},"100583958","quitting-matters-human-immunodeficiency-virus-hybrid-trial-100583958","NCT06883097","Quitting Matters Human Immunodeficiency Virus Hybrid Trial","Hybrid Trial of a Digital Therapeutic for Smoking Cessation Among Persons Living With HIV","QMH","Inclusion Criteria:\n\n1. Self-reported daily cigarette smoking over the past 30 days\n2. Self-reported HIV status\n3. Age 18 or older\n4. Desire to quit smoking\n5. Willing and medically eligible to use NRT\n6. Currently receiving HIV care\n7. Currently owning an Android or iOS smartphone\n\nExclusion Criteria:\n\n1. Current acute psychotic episode or unsafe to participate in the study\n2. Pregnant or intending to become pregnant in the next 6 months\n3. Currently receiving any pharmacological and\u002For behavioral intervention or counseling for smoking cessation\n4. Any medical condition or medication that could compromise subject safety, as determined by the PIs and\u002For study physician\n5. Not able to fluently speak and write in English\n6. Hearing, comprehension, visual, speech, or motor limitations that preclude study participation",{"count":345,"type":21},314,[100],"The purpose of this study is to compare the advantages and disadvantages of two approaches for quitting smoking among people living with HIV (PWH). Participants will complete a 24- week (\\~6-month) study where the Participants will be assigned to one of two smartphone apps to help with quitting smoking. Regardless of the group participants are assigned to, they will also receive a combination of nicotine replacement therapy (patches and gums) that have been shown to help people quit smoking. The main questions this study aims to answer are:\n\nParticipants will complete 5 video call visits over about 6 months. Participants will install their assigned smoking cessation app onto their phone and will be asked to use the app for the duration of the study along with their provided Nicotine Replacement Therapy (NRT) products. During the study visits, participants will meet with study staff to complete questionnaires and interviews. Participants may be asked to provide breath and saliva samples to measure the level of carbon monoxide and nicotine.",[349,350,246,351,27,352,353],"Tobacco","Tobacco Abstinence","Smoking Cessation; Tobacco Dependence","Tobacco Dependence Caused by Cigarettes","Cancer Prevention",[349,246,355,350,356],"Human immunodeficiency virus (HIV)","Quit Smoking","2025-12-15",{"date":359,"type":33},"2025-12-17",{"date":361,"type":33},"2025-08-18",{"date":363,"type":21},"2028-12",{"name":365,"class":116},"Wake Forest University Health Sciences",{"id":367,"slug":368,"hasResults":11,"nctId":369,"briefTitle":370,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":22,"phases":375,"briefSummary":377,"conditions":378,"keywords":380,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":117},"100595320","phase-2-reducing-systemic-inflammation-in-people-on-antiretroviral-therapy-100595320","NCT07030920","Reducing Systemic Inflammation in People on Antiretroviral Therapy","RESTART","Inclusion Criteria:\n\n* 40 years or older, or have lived with HIV for 25 years or more, any sex;\n* Undetectable HIV viral load (defined as last viral load measurement less than 50 copies\u002Fml within the last 6 months);\n* Presence of at least one cardiovascular risk factor among the following: longstanding HIV infection (25 years or more), hypertension, diabetes, past or present smoking, dyslipidemia, family history of early onset CVD in a first-degree relative (defined as younger than 55 in males or younger than 65 in females (80)), known previous cardiovascular disease (defined as past myocardial infarction, coronary revascularization, stroke, or coronary artery atherosclerosis with \\>= 50% stenosis demonstrated on coronary angiography or CCTA);\n* Participants with past cardiovascular disease must be in a stable clinical condition as judged by the study clinicians;\n* Past cardiovascular events are defined as having occurred at least 3 months before screening;\n* Evidence of detectable plasmatic sgp120 levels at any point in the past year, using the assay described priorly and performed at CRCHUM in Dr Andrés Finzi's laboratory.\n\nExclusion Criteria:\n\n* Known allergy to study drug;\n* Concomitant treatment with strong cytochrome P450 (CYP3A) inducers, including but not limited to: carbamazepine, phenytoin (anticonvulsants), mitotane (antineoplastic), enzalutamide (androgen receptor inhibitor), rifampicin (antimycobacterial) and St John's wort (Hypericum perforatum, herbal supplement);\n* Planning to become pregnant, pregnant, or breastfeeding (as requested per product monography (55)). Females of childbearing potential must have a negative pregnancy test at baseline visit, and follow contraception requirements throughout the treatment;\n* Contraindication for CT scan use (estimated glomerular filtration rate \\[eGFR\\] less than 40ml\u002Fmin using the Modification of Diet in Renal Diseases \\[MDRD\\] formula or iodine allergy);\n* Elevated risk of prior ionizing radiation exposure outside clinical care exceeding 10 mSV over 3 years, per the investigator's judgement (eg. a participant with occupational ionizing radiation exposure, prior participation in clinical trials with multiple CT scans)\n* Confirmed uncorrected QT value \\>500ms or confirmed QTcF \\>470 msec for women and \\>450 msec for men;\n* Acquired\u002F congenital long QT syndrome;\n* Current or anticipated treatment with any of the following medications: amiodarone, disopyramide, dofetilide, ibutilide, procainamide, sotalol, and quinidine;\n* Unstable liver disease (as defined by any of the following: presence of ascites, encephalopathy, coagulopathy (INR \\> 2.0), hypoalbuminemia (\\\u003C30 mg\u002Fml), untreated esophageal or gastric varices, or persistently elevated bilirubinemia (\\>1.5x upper limit of normal \\[ULN\\]), known biliary abnormalities (except Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment);\n* ALT \\>=5 times the ULN, OR ALT \\>=3xULN and bilirubin \\>=1.5xULN with \\>35% direct bilirubin;\n* History of liver cirrhosis with CHILD-PUGH classification C;\n* Inability to provide informed consent;\n* Life expectancy of less than 36 months;\n* Inability to present to study visits;\n* Participation in another interventional trial;\n* Known Congestive heart failure with NYHA class 3 or 4.",{"count":374,"type":21},150,[376],"PHASE2","This randomized, open-label clinical trial will evaluate whether adding fostemsavir to current antiretroviral therapy can reduce the risk of cardiovascular disease in people with well-controlled HIV. Researchers will compare imaging, clinical and biomarker outcomes between participants who receive fostemsavir in addition to their existing treatment and those who continue with standard care alone.",[27,379],"Cardiovascular Risk Factor",[381,382,383,384,385,386,379],"Fostemsavir","Rukobia","sgp120","Perivascular fat attenuation index (P-FAI)","uncalcified plaque volume","Systemic inflammation","2025-11-17",{"date":389,"type":33},"2025-11-19",{"date":391,"type":33},"2025-09-30",{"date":393,"type":21},"2029-01",{"name":395,"class":116},"Centre hospitalier de l'Université de Montréal (CHUM)",{"id":397,"slug":398,"hasResults":11,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":403,"enrollmentInfo":404,"targetDuration":4,"studyType":22,"phases":406,"briefSummary":407,"conditions":408,"keywords":411,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":117},"100578667","project-neuroartemis-100578667","NCT06814275","Project neuroARTEMIS","Project ARTEMIS: A Mechanistic Clinical Trial of Neuroimmune Pathways.","Inclusion Criteria:\n\n* 18-59 years old\n* Weekly use of stimulants reported in the past month or a score of 4 or more on the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)\n* Confirmed HIV diagnosis\n* Current receipt of daily oral antiretroviral therapy (ART) medication\n* English fluency\u002Fliteracy\n\nExclusion Criteria:\n\n* Acute brain infection (e.g., neurosyphilis, toxoplasmosis)\n* Acutely symptomatic bipolar I or psychotic disorder\n* Prescription for immunomodulatory medications or other immunotherapy\n* Any MRI contraindications\n* If applicable, on antidepressant medication regimen for at least 2 months","59 Years",{"count":405,"type":21},189,[100],"The purpose of this research is to understand how chronic stress affects the way our brain and immune systems function, and in turn how this affects the way people feel, think, and behave. By learning more about how these processes work, the hope is to be able to develop better treatments to help with problems like depression and substance use. This study is intended for individuals that are HIV positive, currently taking prescription antiretroviral medications, and use stimulants. Through this intervention, the aim is to determine if this positive affect intervention can lead to reductions in stimulant use and depressed mood.",[409,27,410],"Stimulant Use","Depression",[191,412,413,414],"Stimulant use","substance abuse","chronic stress","2025-09-10",{"date":417,"type":33},"2025-09-11",{"date":419,"type":33},"2025-04-29",{"date":421,"type":21},"2028-12-31",{"name":365,"class":116}]